Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
News and Views Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: ORL011
MIFTS: 60

Oral Cancer

Categories: Cancer diseases, Oral diseases, Rare diseases, Smell/Taste diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Oral Cancer

About this section

MalaCards integrated aliases for Oral Cancer:

Name: Oral Cancer 20 36 54 42 3
Lip and Oral Cavity Carcinoma 71
Malignant Neoplasm of Mouth 71

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Smell/Taste diseases Oral diseases
See all MalaCards categories (disease lists)
ICD10: 32


External Ids:

KEGG 36 H00016
ICD10 32 C06.9
UMLS 71 C0153381 C0220641
Sources

Summaries for Oral Cancer

About this section
KEGG : 36 Oral cancer refers to a subgroup of head and neck malignancies that develop at the lips, tongue, salivary glands, gingiva, floor of the mouth, oropharynx, buccal surfaces and other intra-oral locations, according to the International Classification of Diseases. Nevertheless, the term is synonymous to squamous cell carcinoma (SCC) of oral mucosal origin that accounts for more than 90% of all malignant presentations at the aforementioned anatomical sites. Worldwide, oral SCC (OSCC) is the sixth most common cancer; more than 300,000 new cases are diagnosed each year. The development of OSCC is a multistep process requiring the accumulation of multiple genetic alterations, influenced by a patient's genetic predisposition as well as by environmental influences, including tobacco, alcohol, chronic inflammation, and viral infection. The genetic changes include activation of the epidermal growth factor receptor (EGFR), alterations of tumor suppressors p53 and p16, and cyclin D1 overexpression.

MalaCards based summary : Oral Cancer, also known as lip and oral cavity carcinoma, is related to oral leukoplakia and leukoplakia, and has symptoms including snoring and halitosis. An important gene associated with Oral Cancer is MIR31 (MicroRNA 31), and among its related pathways/superpathways are Endometrial cancer and Drug metabolism - cytochrome P450. The drugs Racepinephrine and Dopexamine have been mentioned in the context of this disorder. Affiliated tissues include tongue, lymph node and endothelial, and related phenotypes are Reduced mammosphere formation and digestive/alimentary

GARD : 20 Oral cancer includes cancers of the mouth, lips, and oropharynx (the part of the throat at the back of the mouth). Most cases are designated as squamous cell carcinomas because they begin in the flat cells (squamous cells) that cover the surfaces of the mouth, tongue, and lips. About 42,000 individuals in the United Stated are diagnosed with oral cancer each year. Most cases occur in people over age 40. Men are twice as likely to be affected as women. The use of alcohol and/or tobacco is associated with approximately 75 percent of oral cancers. Other risk factors include HPV, a sexually transmitted disease; increasing age; sun exposure; and a poor diet. Treatment for oral cancer may include surgery, radiation therapy, chemotherapy, or targeted therapy.

MedlinePlus : 42 Oral cancer can form in any part of the mouth. Most oral cancers begin in the flat cells that cover the surfaces of your mouth, tongue, and lips. Anyone can get oral cancer, but the risk is higher if you are male, use tobacco, drink lots of alcohol, have HPV, or have a history of head or neck cancer. Frequent sun exposure is also a risk factor for lip cancer. Symptoms of oral cancer include White or red patches in your mouth A mouth sore that won't heal Bleeding in your mouth Loose teeth Problems or pain with swallowing A lump in your neck An earache Tests to diagnose oral cancer include a physical exam, endoscopy, biopsy, and imaging tests. Oral cancer treatments may include surgery, radiation therapy, and chemotherapy. Some patients have a combination of treatments. NIH: National Cancer Institute

CDC : 3 In 2012, there were nearly 40,000 new cases of cancer of the oral cavity and pharynx diagnosed in the United States and nearly 9,000 deaths. The 5-year survival rate for these cancers is about 59 percent. Mortality from oral cancer is nearly twice as high in some minorities (especially black males) as it is in whites. Preventing high risk behaviors, that include cigarette, cigar or pipe smoking, use of smokeless tobacco, and excessive use of alcohol are critical in preventing oral cancers. Early detection is key to increasing the survival rate for these cancers. Oral Human Papilloma Virus (HPV), the most common sexually transmitted disease, can cause cancers in the back of the throat, called "oropharyngeal cancers." More research is needed to determine whether HPV itself causes oropharyngeal cancers, or if other factors (such as smoking or chewing tobacco) interact with HPV to cause these cancers.

Wikipedia : 74 Oral cancer, also known as mouth cancer, is cancer of the lining of the lips, mouth, or upper throat. In... more...

Sources

Related Diseases for Oral Cancer

About this section

Diseases related to Oral Cancer via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 499)
# Related Disease Score Top Affiliating Genes
1 oral leukoplakia 31.6 GSTT1 GSTM1 CCND1
2 leukoplakia 31.4 KRT13 GSTT1 GSTM1 CYP1A1
3 oral squamous cell carcinoma 31.3 TP53 MMP9 MIR31 MIR21 EGFR CDKN2A
4 squamous cell papilloma 31.3 TP53 CDKN2A
5 oropharynx cancer 31.1 TP53 EGFR CDKN2A CDH1 CCND1
6 oral submucous fibrosis 31.0 TP53 PTGS2 MMP9 GSTM1 CYP1A1 CDH1
7 oral cavity cancer 30.9 MIR31 MIR21 GSTM1 EGFR CYP1A1
8 in situ carcinoma 30.8 TP53 EGFR CDKN2A CDH1 CCND1
9 tongue carcinoma 30.7 TP53 PTGS2 MMP9 MIR31 MIR21 CDH1
10 papilloma 30.6 TP53 PTGS2 KRT13 EGFR CDKN2A CCND1
11 squamous cell carcinoma 30.5 TP53 PTGS2 MMP9 KRT19 EGFR CYP1A1
12 tongue squamous cell carcinoma 30.5 TP53 MMP9 MIR21 EGFR CDKN2A CDH1
13 salivary gland carcinoma 30.4 TP53 GSTM1 EGFR CDKN2A
14 lip and oral cavity cancer 30.4 TP53 EGFR CDKN2A
15 verrucous carcinoma 30.3 TP53 MMP9 MIR31 EGFR CDKN2A CCND1
16 mutagen sensitivity 30.2 TP53 GSTT1 GSTM1 CCND1
17 human papillomavirus infectious disease 30.2 TP53 KRT13 CDKN2A
18 familial adenomatous polyposis 30.1 TP53 PTGS2 CDH1 CCND1
19 li-fraumeni syndrome 30.1 TP53 EGFR CDKN2A CDH1
20 anus cancer 30.0 TP53 EGFR CDKN2A
21 adenoid cystic carcinoma 30.0 TP53 MMP9 KRT19 EGFR CDKN2A CDH1
22 hypopharynx cancer 29.9 TP53 EGFR CDKN2A CDH1
23 tonsil cancer 29.9 TP53 EGFR CDKN2A CDH1
24 keratocystic odontogenic tumor 29.9 TP53 PTGS2 MMP9 CCND1
25 testicular cancer 29.9 TP53 GSTM1 EGFR CDH1
26 small cell carcinoma 29.8 TP53 KRT19 EGFR CDKN2A
27 mucoepidermoid carcinoma 29.8 TP53 KRT19 KRT13 EGFR CDKN2A CDH1
28 breast adenocarcinoma 29.8 TP53 MMP9 EGFR CYP1A1
29 cervical squamous cell carcinoma 29.8 TP53 EGFR CDKN2A CDH1 CCND1
30 adenoma 29.8 TP53 PTGS2 CDKN2A CDH1 CCND1
31 suppressor of tumorigenicity 3 29.7 TP53 CDKN2A
32 pharynx cancer 29.7 TP53 MIR31 MIR21 GSTM3 GSTM1 EGFR
33 adenocarcinoma 29.7 TP53 PTGS2 MMP9 EGFR CDKN2A CDH1
34 kidney cancer 29.7 TP53 MIR21 EGFR CDKN2A
35 skin melanoma 29.7 TP53 PTGS2 MMP9 EGFR CDKN2A CDH1
36 myeloma, multiple 29.6 TP53 MIR21 EGFR CDKN2A CCND1
37 leukemia, acute lymphoblastic 29.5 TP53 MIR21 GSTM1 CYP1A1 CDKN2A
38 colon adenocarcinoma 29.5 TP53 PTGS2 MIR21 EGFR CDH1 CCND1
39 laryngeal squamous cell carcinoma 29.5 TP53 MIR21 KRT19 GSTM3 GSTM1 EGFR
40 lower lip cancer 29.4 MIR345 MIR31 MIR21
41 cervical cancer 29.4 TP53 RARB PTGS2 MIR31 MIR21 KRT19
42 basal cell carcinoma 29.3 TP53 PTGS2 MMP9 KRT19 GSTT1 GSTM3
43 nasopharyngeal carcinoma 29.2 TP53 MMP9 MIR31 MIR21 KRT13 GSTM1
44 lung squamous cell carcinoma 29.2 TP53 RARB KRT19 EGFR CYP1A1 CDKN2A
45 larynx cancer 29.2 TP53 MIR31 MIR21 GSTT1 GSTM3 GSTM1
46 leukemia, acute myeloid 29.1 TP53 MIR31 MIR21 EGFR CDKN2A CDH1
47 squamous cell carcinoma, head and neck 29.1 TP53 RARB PTGS2 MMP9 MIR31 MIR21
48 esophageal cancer 28.9 TP53 RARB PTGS2 MMP9 MIR31 MIR21
49 skin carcinoma 28.9 TP53 PTGS2 MMP9 MIR31 MIR21 KRT19
50 gastric cancer 28.5 TP53 RARB PTGS2 MMP9 MIR21 KRT19

Graphical network of the top 20 diseases related to Oral Cancer:



Diseases related to Oral Cancer
Sources

Symptoms & Phenotypes for Oral Cancer

About this section

UMLS symptoms related to Oral Cancer:


snoring, halitosis

GenomeRNAi Phenotypes related to Oral Cancer according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Reduced mammosphere formation GR00396-S 9.17 CCND1 CDH1 EGFR GSTM1 GSTM3 PTGS2

MGI Mouse Phenotypes related to Oral Cancer:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 digestive/alimentary MP:0005381 10.02 ANO1 CCND1 CDH1 CDKN2A EGFR KRT19
2 integument MP:0010771 9.91 ANO1 CCND1 CDH1 CDKN2A EGFR KRT19
3 neoplasm MP:0002006 9.76 CCND1 CDH1 CDKN2A EGFR KRT19 MMP9
4 no phenotypic analysis MP:0003012 9.5 CDH1 CDKN2A CYP1A1 EGFR KRT19 PTGS2
5 respiratory system MP:0005388 9.28 ANO1 CCND1 CDKN2A EGFR KRT19 MMP9
Sources

Drugs & Therapeutics for Oral Cancer

About this section

Drugs for Oral Cancer (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 95)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Racepinephrine Approved Phase 4 329-65-7 838
2
Dopexamine Approved, Investigational Phase 4 86197-47-9 55483
3
Norepinephrine Approved Phase 4 51-41-2 439260
4
Dobutamine Approved Phase 4 34368-04-2 36811
5
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
6 Respiratory System Agents Phase 4
7 Adrenergic alpha-Agonists Phase 4
8 Dopamine agonists Phase 4
9 Cardiotonic Agents Phase 4
10 Protective Agents Phase 4
11 Anti-Asthmatic Agents Phase 4
12 Adrenergic beta-Agonists Phase 4
13 Epinephryl borate Phase 4
14 Adrenergic Agents Phase 4
15 Mydriatics Phase 4
16 Sympathomimetics Phase 4
17 Bronchodilator Agents Phase 4
18 Vasoconstrictor Agents Phase 4
19 Vasodilator Agents Phase 4
20 Adrenergic Agonists Phase 4
21
Heparin Approved, Investigational Phase 3 9005-49-6 772 9812414
22
Zinc sulfate Approved, Investigational Phase 3 7733-02-0
23
Zinc Approved, Investigational Phase 3 7440-66-6 32051
24
Fluorouracil Approved Phase 3 51-21-8 3385
25
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
26 Hemostatics Phase 3
27 Tolonium Chloride Phase 3
28 Coagulants Phase 3
29 calcium heparin Phase 3
30 Trace Elements Phase 3
31 Dermatologic Agents Phase 3
32 Nutrients Phase 3
33 Micronutrients Phase 3
34
Erlotinib Hydrochloride Phase 3 183319-69-9 176871
35
Celecoxib Approved, Investigational Phase 2 169590-42-5 2662
36 Raspberry Approved Phase 1, Phase 2
37 Orange Approved Phase 1, Phase 2
38
Aminolevulinic acid Approved Phase 1, Phase 2 106-60-5 137
39
Cetuximab Approved Phase 2 205923-56-4 56842117 2333
40
Hydroxyurea Approved Phase 1, Phase 2 127-07-1 3657
41
Metformin Approved Phase 2 657-24-9 14219 4091
42
Eniluracil Investigational Phase 1, Phase 2 59989-18-3
43 Plasminogen Phase 2
44 Anti-Inflammatory Agents Phase 2
45 Analgesics, Non-Narcotic Phase 2
46 Cyclooxygenase Inhibitors Phase 2
47 Anti-Inflammatory Agents, Non-Steroidal Phase 2
48 Cyclooxygenase 2 Inhibitors Phase 2
49 Antirheumatic Agents Phase 2
50 Analgesics Phase 2

Interventional clinical trials:

(show top 50) (show all 120)
# Name Status NCT ID Phase Drugs
1 Cancer Chemoprevention by Metformin Hydrochloride Compared to Placebo in Oral Potentially Malignant Lesions: A Randomised Clinical Trial Unknown status NCT03684707 Phase 4 Metformin Hcl 500Mg 24Hr Sa Tab
2 An Assessment of the Effects of Pressors on Graft Blood Flow After Free Tissue Transfer Surgery: A Randomised Study Completed NCT01418118 Phase 4 Epinephrine;Norepinephrine;Dobutamine;Dopexamine
3 The Optimal Neck Treatments Strategy of Early Oral Cancer Based on Adverse Pathological Factor Recruiting NCT03017053 Phase 4
4 Canadian Optically Guided Approach for Oral Lesions Surgical Trial - COOLS Unknown status NCT01039298 Phase 3
5 Comparing the Test Characteristics of Three Oral Cancer Screening Techniques:1)Unaided Visual Examination 2)VelScope Examination and 3)Toluidine Blue Application, by Trained Primary Health Care Workers in Mumbai, India. Unknown status NCT00655421 Phase 3
6 Cancer Chemoprevention by Metformin Hydrochloride Compared to Placebo in Oral Potentially Malignant Lesions: A Randomized Clinical Trial (Part 1) Unknown status NCT03685409 Phase 3 Metformin Hydrochloride 500 MG;Placebo Oral Tablet
7 Phase III Trial of Intensity-modulated Radiotherapy Plus Cisplatin Versus Conventional Radiotherapy Plus Cisplatin in Patients With Stage III-IV Head and Neck Squamous Cell Carcinoma Completed NCT00158678 Phase 3 concomitant cisplatin
8 Efficacy of Zinc Sulfate on Concurrent Chemoradiotherapy Induced Taste Alterations in Oral Cancer Patients- A Double Blind Randomized Controlled Trial Completed NCT03824925 Phase 3 Placebo oral Zinc capsule;Zinc Sulfate 220 MG
9 Phase III Trial Comparing Conventional RT With Concomitant CT Versus Accelerated RT With Concomitant CT Versus Very Accelerated RT Alone in Patients With Head and Neck Squamous Cell Carcinoma Completed NCT00158652 Phase 3 5FU, Paraplatin
10 Erlotinib Prevention of Oral Cancer (EPOC) Completed NCT00402779 Phase 3 Erlotinib;Placebo
11 Workplace Tobacco Cessation And Oral Cancer Screening Study Completed NCT00750503 Phase 3
12 Enhancing Self Care Among Oral Cancer Survivors: The Empowered Survivor Trial Recruiting NCT04713449 Phase 3
13 Evaluation of OraTest in Combination With Visual Examination in the Improved Detection of Oral Mucosal Lesions Suspicious of Serious Pathology in High-Risk Patients for the Purpose of Referral to the Health Care Professional Experienced in Oral Cancer: Phase III Clinical Trial Comparing the Sensitivity and Assessing the Specificity of OraTest in Combination With Visual Examination and Visual Examination Alone in Patients at High Risk as Defined by Age and Lifestyle Factors (ZIL-401) Terminated NCT00537199 Phase 3 OraTest
14 Phase II Trial: uPAR PET/CT for Staging Advanced and Localised Oral and Oropharyngeal Cancer Unknown status NCT02960724 Phase 2
15 Phrase II Single Arm Study of Effect of FDG-PET/CT for Simulation and Radiation Treatment Planning in Oral Unknown status NCT03008694 Phase 2
16 Development of Novel Diagnostic Tools and Therapeutic Strategies for Oral Cancer Unknown status NCT02739204 Phase 2 Celecoxib
17 Food-Based Modulation of Biomarkers in Human Tissues at High-Risk for Oral Cancer Completed NCT01469429 Phase 1, Phase 2 chemoprevention;chemoprevention
18 A Phase 2a Randomized, Parallel Group, Open Label, Multicenter Study to Assess the Safety and Efficacy of RRx-001 in the Attenuation of Oral Mucositis in Patients Receiving Chemoradiation for the Treatment of Locally Advanced Squamous Cell Carcinoma of the Oral Cavity or Oropharynx Completed NCT03515538 Phase 2 RRx-001;Cisplatin for injection
19 A Study of the Effects of PEITC on Oral Cells With Mutant p53 Completed NCT01790204 Phase 1, Phase 2
20 Low-cost Enabling Technology for Image-guided Photodynamic Therapy (PDT) of Oral Completed NCT03638622 Phase 1, Phase 2
21 A Phase II Study of Neoadjuvant Bio-chemotherapy With Cetuximab, Paclitaxel, and Cisplatin (CPC) Followed by Cetuximab-based Concurrent Bio-radiotherapy in High-risk Locally Advanced Oral Squamous Cell Carcinoma (OSCC) Completed NCT00933387 Phase 2 Cetuximab,Paclitaxel,Cisplatin
22 Efficacy of Implant-Supported Maxillofacial Prostheses Completed NCT00006341 Phase 2
23 Clinical Evaluation of Bioadhesive Gels for Oral Cancer Chemoprevention Completed NCT01192204 Phase 1, Phase 2 10% FBR containing bioadhesive gel;placebo gel
24 A Phase I Study of Concomitant Chemoradiotherapy With 776C85, 5-FU and Hydroxyurea for Patients With Poor Prognosis Oral Cancer Completed NCT00004901 Phase 1, Phase 2 ethynyluracil;fluorouracil;hydroxyurea
25 M4OC-Prevent: Metformin for Oral Cancer Prevention Active, not recruiting NCT02581137 Phase 2 Metformin Hydrochloride
26 Evaluation of Photobiomodumation Using LED Lamp as a Curative Treatment for Oral or Oropharyngeal Mucositic Inducted by Radiation Therapy Not yet recruiting NCT04251949 Phase 2
27 Guided by Light: Optimizing Surgical Excision of Oral Cancer Using Real-time Fluorescence Imaging Not yet recruiting NCT04191460 Phase 2 cRGD-ZW800-1.
28 Evaluation of Polarized Reflectance Spectroscopy for Detection of High-risk Oral Lesions Completed NCT01604759 Phase 1
29 Inductive Toripalimab and Paclitaxel/Cisplatin on Pathological Response in Oral Squamous Cell Carcinoma Patients: A Single-arm Phase I Trial Recruiting NCT04473716 Phase 1 Toripalimab;Paclitaxcel;Cisplatin
30 Inductive Camrelizumab and Apatinib for Patients With Locally Advanced and Resectable Oral Squamous Cell Carcinoma: A Single-arm Phase I Trial Recruiting NCT04393506 Phase 1 Camrelizumab;Apatinib
31 "Safety and Tolerability of Neoadjuvant Nivolumab for Locally Advanced Resectable Oral Cancer Combined With [18F] BMS-986192 / [18F] -FDG PET Imaging and Immunomonitoring for Response Prediction" Recruiting NCT03843515 Phase 1 Nivolumab
32 PK Analysis of Antitumor B in Patients With Oral Cancer Not yet recruiting NCT03459729 Phase 1 Antitumor B
33 Evaluation of Diagnostic Aids for Detection and Diagnosis of Oral Cancer Withdrawn NCT02251639 Phase 1
34 The Role of SDF-1/CXCR4 in Metastasis of Oral Squamous Cell Carcinoma Unknown status NCT00173849
35 Expression of Hypoxia-Inducible Factor-α in Oral Precancers and Cancers Unknown status NCT00154973
36 Shoulder Function After Level IIB Neck Dissection: A Randomized Controlled Unknown status NCT00765791 Early Phase 1
37 Diagnosis of Oral Precancers and Cancers Using Optic Coherence Tomography Unknown status NCT00172965
38 Therapeutic Effect Of Luteolin Natural Extract Versus Its Nanoparticles On Tongue Squamous Cell Carcinoma Cell Line: In Vitro Study Unknown status NCT03288298 Early Phase 1 luteolin;nano-luteolin
39 Observational Study on the Carcinogenesis of SOX-9 in Oral Cancer, and Chemopreventive Possibility for the Treatment of Oral Cancer Using SOX-9 Inhibitor. Unknown status NCT01919567
40 Observational Study on the Carcinogenesis of Gα12 in Oral Cancer, and Chemopreventive Possibility for the Treatment of Oral Cancer Using Ga12 Inhibitor. Unknown status NCT01919580
41 Elective Versus Therapeutic Neck Dissection in the Treatment of Early Node Negative Squamous Cell Carcinoma of the Oral Cavity Unknown status NCT00193765
42 The Role of Lymphangiogenesis in Head and Neck Cancer Metastasis Unknown status NCT00173381
43 The Role of Vascular Endothelial Growth Factor-C (VEGF-C) and Its Receptors Induced Lymphangiogenesis on the Carcinogenesis of Oral Cancers and Premalignant Lesions Unknown status NCT00173316
44 Dual-time PET/CT and Sentinel Node Diagnostics Preoperatively in Patients With Oral Cancer Unknown status NCT01136265
45 The Role of microRNA-29b in the Oral Squamous Cell Carcinoma Unknown status NCT02009852
46 Oral State of Patients Affected by an Oral Cancer Before and After Radiotherapy - 3-years Prospective Study Unknown status NCT02866500
47 Postoperative Radiotherapy According to Molecular Analysis of Surgical Margins of Early Stages Oral and Oropharyngeal Squamous Cell Carcinomas: A Prospective Study Unknown status NCT00232960
48 The Relation of Microtubule-Associated Protein 2 and Cell Migration Unknown status NCT00174109
49 Validation of DNA Methylation Biomarkers for Oral Cancer Detection-Follow up Study Unknown status NCT02902406
50 A Prospective, Randomized, Clinical Study to Evaluate the Effects of Early Enteral Nutritional Supplementation on Clinical Outcomes in Patients With Oral Cancer Undergoing Radio(Chemo)Therapy After Surgical Resection Unknown status NCT03545490

Search NIH Clinical Center for Oral Cancer

Sources

Genetic Tests for Oral Cancer

About this section
Sources

Anatomical Context for Oral Cancer

About this section

MalaCards organs/tissues related to Oral Cancer:

40
Tongue, Lymph Node, Endothelial, Myeloid, Bone, Salivary Gland, Neutrophil
Sources

Publications for Oral Cancer

About this section

Articles related to Oral Cancer:

(show top 50) (show all 12226)
# Title Authors PMID Year
1
Increase of microRNA miR-31 level in plasma could be a potential marker of oral cancer. 61 47
20233326 2010
2
T-regulatory cell/T helper 17 cell imbalance functions as prognostic biomarker of oral squamous cell carcinoma - CONSORT. 42
33285688 2020
3
Randomised clinical trial on 7-days-a-week postoperative radiotherapy vs. concurrent postoperative radio-chemotherapy in locally advanced cancer of the oral cavity/oropharynx. 42
32960662 2020
4
Traditional Chinese medicine for oral squamous cell carcinoma: A Bayesian network meta-analysis protocol. 42
33120858 2020
5
Diagnostic clinical aids in oral cancer. 54 61
20371204 2010
6
Fatty-acid-binding protein 5 promotes cell proliferation and invasion in oral squamous cell carcinoma. 54 61
20040021 2010
7
Epidermal growth factor receptor regulates beta-catenin location, stability, and transcriptional activity in oral cancer. 61 54
20302655 2010
8
Detection of N-, H-, and KRAS codons 12, 13, and 61 mutations with universal RAS primer multiplex PCR and N-, H-, and KRAS-specific primer extension. 61 54
19879255 2010
9
Transactivation and expression patterns of Jun and Fos/AP-1 super-family proteins in human oral cancer. 61 54
19653276 2010
10
[Expression of survivin, caspase-3 in oral precancerous lesions and oral squamous-cell carcinoma]. 61 54
20368001 2010
11
KO-202125, a sauristolactam derivate, induces apoptosis to prevent KB human oral squamous carcinoma cells through inhibition of cyclooxygenase-2 expression. 61 54
19910795 2010
12
Modulation of EGFR by oral squamous cell carcinoma cell lines. 54 61
20066875 2009
13
The association between hypoxia inducible factor-1alpha gene polymorphisms and increased susceptibility to oral cancer. 54 61
19717330 2009
14
S-allylcysteine modulates the expression of E-cadherin and inhibits the malignant progression of human oral cancer. 54 61
19157822 2009
15
Identification of a microRNA signature associated with progression of leukoplakia to oral carcinoma. 47
19776030 2009
16
Significance of promoter hypermethylation of p16 gene for margin assessment in carcinoma tongue. 54 61
19431196 2009
17
Evaluation of the cytotoxic and genotoxic effects of orthodontic bonding adhesives upon human gingival papillae through immunohistochemical expression of p53, p63 and p16. 61 54
19846940 2009
18
Study on TP53 codon 72 polymorphisms with oral carcinoma susceptibility. 54 61
20082880 2009
19
Role of nitric oxide and antioxidant enzymes in the pathogenesis of oral cancer. 54 61
20160357 2009
20
Contribution of genetic polymorphisms of stromal cell-derived factor-1 and its receptor, CXCR4, to the susceptibility and clinicopathologic development of oral cancer. 61 54
19373784 2009
21
Protective role of Withaferin-A on immunoexpression of p53 and bcl-2 in 7,12-dimethylbenz(a)anthracene-induced experimental oral carcinogenesis. 54 61
19009234 2009
22
Polymorphisms at p53, p73, and MDM2 loci modulate the risk of tobacco associated leukoplakia and oral cancer. 54 61
19204927 2009
23
CCL5/CCR5 axis promotes the motility of human oral cancer cells. 61 54
19334035 2009
24
Detection of survivin and p53 in human oral cancer: correlation with clinicopathologic findings. 61 54
19340865 2009
25
Polymorphisms in the hypoxia inducible factor 1-alpha and the impact on the prognosis of early stages of oral cancer. 54 61
19449077 2009
26
Expression of Fas/FasL in patients with oral lichen planus. 61 54
19810143 2009
27
Expression of FLJ10540 is correlated with aggressiveness of oral cavity squamous cell carcinoma by stimulating cell migration and invasion through increased FOXM1 and MMP-2 activity. 61 54
19525975 2009
28
RNAi targeting urokinase-type plasminogen activator receptor inhibits metastasis and progression of oral squamous cell carcinoma in vivo. 61 54
19391133 2009
29
Overexpression of DPAGT1 leads to aberrant N-glycosylation of E-cadherin and cellular discohesion in oral cancer. 54 61
19549906 2009
30
MDM2 SNP309 does not confer an increased risk to oral squamous cell carcinoma but may modulate the age of disease onset. 54 61
18804411 2009
31
Ribonucleotide reductase small subunit p53R2 promotes oral cancer invasion via the E-cadherin/beta-catenin pathway. 61 54
18804405 2009
32
Matrix metalloproteinases (MMP) 1 and MMP10 but not MMP12 are potential oral cancer markers. 54 61
19489686 2009
33
Cyclooxygenase-2 gene polymorphisms reduce the risk of oral premalignant lesions. 61 54
19197984 2009
34
Pin1 overexpression is associated with poor differentiation and survival in oral squamous cell carcinoma. 61 54
19288014 2009
35
Expression of metallothionein and p53 antigens are correlated in oral squamous cell carcinoma. 54 61
19414363 2009
36
Immunoexpression of cyclooxygenase-2 and p53 in oral squamous cell carcinoma. 61 54
19239949 2009
37
Functional genomic analysis identified epidermal growth factor receptor activation as the most common genetic event in oral squamous cell carcinoma. 54 61
19276369 2009
38
Prevalence of CYP1A1 and GST polymorphisms in the population of northeastern India and susceptibility of oral cancer. 54 61
19718946 2009
39
Oral epithelial hyperplasia in diabetes mellitus. 54 61
20067171 2009
40
E-Cadherin truncation and sialyl Lewis-X overexpression in oral squamous cell carcinoma and oral precancerous conditions. 54 61
19152244 2009
41
Expression of p16 in oral cancer and premalignant lesions. 54 61
19192055 2009
42
Comparative study on the immunogenicity between an HLA-A24-restricted cytotoxic T-cell epitope derived from survivin and that from its splice variant survivin-2B in oral cancer patients. 61 54
19123955 2009
43
CYP1A1 and GSTM1 polymorphisms and oral cancer risk: association studies via evidence-based meta-analyses. 61 54
19160101 2009
44
Telomere attrition and telomerase activity are associated with GSTM1 polymorphism in oral cancer. 54 61
19729828 2009
45
GSTM1, GSTT1 and CYP1A1 polymorphisms and risk of oral cancer: a case-control study in Jakarta, Indonesia. 54 61
19469619 2009
46
RNAi-mediated downregulation of urokinase plasminogen activator receptor inhibits proliferation, adhesion, migration and invasion in oral cancer cells. 54 61
18486529 2008
47
Effects of epidermal growth factor on the invasion activity of the oral cancer cell lines HSC3 and SAS. 54 61
18485796 2008
48
Multiple aberrations of chromosome 3p detected in oral premalignant lesions. 54 61
19138989 2008
49
Combined effects of the p53 codon 72 and p73 G4C14-to-A4T14 polymorphisms on the risk of HPV16-associated oral cancer in never-smokers. 54 61
18701437 2008
50
Tobacco, antioxidant enzymes, oxidative stress, and genetic susceptibility in oral cancer. 61 54
18838881 2008
Sources

Variations for Oral Cancer

About this section

Cosmic variations for Oral Cancer:

9 (show top 50) (show all 888)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM87278348 ZFHX3 salivary gland,NS,carcinoma,squamous cell carcinoma c.8617G>A p.E2873K 16:72794065-72794065 0
2 COSM102027267 ZFHX3 salivary gland,NS,carcinoma,squamous cell carcinoma c.5875G>A p.E1959K 16:72794065-72794065 0
3 COSM149281700 ZFHX3 salivary gland,NS,carcinoma,squamous cell carcinoma c.8617G>A p.E2873K 16:72794065-72794065 0
4 COSM131674386 WASF2 salivary gland,mouth floor,carcinoma,NS c.15G>T p.T5= 1:27428876-27428876 0
5 COSM143041461 WASF2 salivary gland,mouth floor,carcinoma,NS c.15G>T p.T5= 1:27428876-27428876 0
6 COSM148984630 TSC2 salivary gland,NS,carcinoma,squamous cell carcinoma c.2276G>A p.R759K 16:2072904-2072904 0
7 COSM87031764 TSC2 salivary gland,NS,carcinoma,squamous cell carcinoma c.2276G>A p.R759K 16:2072904-2072904 0
8 COSM101183796 TSC2 salivary gland,NS,carcinoma,squamous cell carcinoma c.2129G>A p.R710K 16:2072904-2072904 0
9 COSM136620677 TSC2 salivary gland,NS,carcinoma,squamous cell carcinoma c.2309G>A p.R770K 16:2072904-2072904 0
10 COSM151372405 TSC2 salivary gland,NS,carcinoma,squamous cell carcinoma c.2276G>A p.R759K 16:2072904-2072904 0
11 COSM150578398 TSC2 salivary gland,NS,carcinoma,squamous cell carcinoma c.2276G>A p.R759K 16:2072904-2072904 0
12 COSM90407063 TSC2 salivary gland,NS,carcinoma,squamous cell carcinoma c.2276G>A p.R759K 16:2072904-2072904 0
13 COSM110106925 TSC2 salivary gland,NS,carcinoma,squamous cell carcinoma c.2165G>A p.R722K 16:2072904-2072904 0
14 COSM151515117 TSC2 salivary gland,NS,carcinoma,squamous cell carcinoma c.2276G>A p.R759K 16:2072904-2072904 0
15 COSM150317141 TSC2 salivary gland,NS,carcinoma,squamous cell carcinoma c.2276G>A p.R759K 16:2072904-2072904 0
16 COSM147697382 TSC2 salivary gland,NS,carcinoma,squamous cell carcinoma c.2276G>A p.R759K 16:2072904-2072904 0
17 COSM151749446 TSC2 salivary gland,NS,carcinoma,squamous cell carcinoma c.2276G>A p.R759K 16:2072904-2072904 0
18 COSM102621798 TSC2 salivary gland,NS,carcinoma,squamous cell carcinoma c.2276G>A p.R759K 16:2072904-2072904 0
19 COSM150357913 TSC2 salivary gland,NS,carcinoma,squamous cell carcinoma c.2276G>A p.R759K 16:2072904-2072904 0
20 COSM149805510 TSC2 salivary gland,NS,carcinoma,squamous cell carcinoma c.2276G>A p.R759K 16:2072904-2072904 0
21 COSM84855029 TRPV5 salivary gland,mouth floor,carcinoma,NS c.554A>G p.H185R 7:142929054-142929054 0
22 COSM110312003 TRPV5 salivary gland,mouth floor,carcinoma,NS c.554A>G p.H185R 7:142929054-142929054 0
23 COSM113659175 TP53BP1 salivary gland,mouth floor,carcinoma,NS c.3869C>G p.T1290S 15:43422086-43422086 0
24 COSM99562983 TP53BP1 salivary gland,mouth floor,carcinoma,NS c.3869C>G p.T1290S 15:43422086-43422086 0
25 COSM99625361 TP53BP1 salivary gland,mouth floor,carcinoma,NS c.3869C>G p.T1290S 15:43422086-43422086 0
26 COSM86842324 TP53BP1 salivary gland,mouth floor,carcinoma,NS c.3854C>G p.T1285S 15:43422086-43422086 0
27 COSM112263900 TP53 salivary gland,NS,carcinoma,squamous cell carcinoma c.949C>T p.Q317* 17:7673579-7673579 0
28 COSM106063834 TP53 salivary gland,NS,carcinoma,squamous cell carcinoma c.949C>T p.Q317* 17:7673579-7673579 0
29 COSM145028043 TP53 salivary gland,NS,carcinoma,squamous cell carcinoma c.832C>T p.Q278* 17:7673579-7673579 0
30 COSM121875754 TP53 salivary gland,NS,carcinoma,squamous cell carcinoma c.263A>G p.Y88C 17:7674872-7674872 0
31 COSM142845131 TP53 salivary gland,NS,carcinoma,squamous cell carcinoma c.832C>T p.P278S 17:7673788-7673788 0
32 COSM87915681 TP53 salivary gland,NS,carcinoma,squamous cell carcinoma c.310C>T p.Q104* 17:7676059-7676059 0
33 COSM144019757 TP53 salivary gland,minor,carcinoma,NS c.742G>T p.D248Y 17:7674188-7674188 0
34 COSM106059381 TP53 salivary gland,minor,carcinoma,NS c.775G>T p.D259Y 17:7674188-7674188 0
35 COSM122741193 TP53 salivary gland,NS,carcinoma,squamous cell carcinoma c.191G>C p.R64P 17:7674944-7674944 0
36 COSM142848375 TP53 salivary gland,NS,carcinoma,squamous cell carcinoma c.310C>T p.Q104* 17:7676059-7676059 0
37 COSM144087150 TP53 salivary gland,NS,carcinoma,squamous cell carcinoma c.-27C>T p.? 17:7675161-7675161 0
38 COSM144090807 TP53 salivary gland,NS,carcinoma,squamous cell carcinoma c.305+1G>T p.? 17:7674180-7674180 0
39 COSM144087282 TP53 salivary gland,NS,carcinoma,squamous cell carcinoma c.340C>T p.R114C 17:7673803-7673803 0
40 COSM121876058 TP53 salivary gland,NS,carcinoma,squamous cell carcinoma c.55C>T p.P19S 17:7675161-7675161 0
41 COSM142560569 TP53 salivary gland,NS,carcinoma,squamous cell carcinoma c.700C>T p.R234C 17:7673803-7673803 0
42 COSM144310260 TP53 salivary gland,NS,carcinoma,squamous cell carcinoma c.334C>T p.P112S 17:7675161-7675161 0
43 COSM87905712 TP53 salivary gland,minor,carcinoma,NS c.775G>T p.D259Y 17:7674188-7674188 0
44 COSM142837171 TP53 salivary gland,NS,carcinoma,squamous cell carcinoma c.725G>A p.C242Y 17:7674238-7674238 0
45 COSM144095010 TP53 salivary gland,NS,carcinoma,squamous cell carcinoma c.472C>T p.Q158* 17:7673579-7673579 0
46 COSM105627143 TP53 salivary gland,minor,carcinoma,NS c.775G>T p.D259Y 17:7674188-7674188 0
47 COSM143165482 TP53 salivary gland,NS,carcinoma,squamous cell carcinoma c.472C>T p.Q158* 17:7673579-7673579 0
48 COSM105636071 TP53 salivary gland,NS,carcinoma,squamous cell carcinoma c.310C>T p.Q104* 17:7676059-7676059 0
49 COSM143946884 TP53 salivary gland,minor,carcinoma,NS c.*13-1G>A p.? 17:7670716-7670716 0
50 COSM142837225 TP53 salivary gland,NS,carcinoma,squamous cell carcinoma c.659A>G p.Y220C 17:7674872-7674872 0

Copy number variations for Oral Cancer from CNVD:

7 (show top 50) (show all 92)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 16000 1 120982663 144003083 Loss Oral cancer
2 18683 1 147134204 147499075 Loss Oral cancer
3 22566 1 167493797 167507911 Loss NME7 Oral cancer
4 25915 1 195026732 195048237 Gain Oral cancer
5 25916 1 195026732 195104236 Gain Oral cancer
6 30920 1 246713386 246852155 Loss Oral cancer
7 35162 1 604268 4312064 Gain Oral cancer
8 41154 10 138235 42150788 Loss Oral cancer
9 42635 10 37475290 37508431 Loss Oral cancer
10 43408 10 46396192 46516611 Loss Oral cancer
11 48616 11 101407278 102165885 Gain Oral cancer
12 49060 11 102611683 110151240 Loss Oral cancer
13 50726 11 119044645 133316524 Loss Oral cancer
14 52672 11 186966 2789993 Gain Oral cancer
15 55431 11 52900000 134452384 Gain Oral cancer
16 56752 11 60970713 78077527 Gain Oral cancer
17 58595 11 68654476 70150073 Gain Oral cancer
18 79103 13 6365 44752 Loss Oral cancer
19 82813 14 15600000 106368585 Gain Oral cancer
20 83220 14 19560721 22142166 Gain Oral cancer
21 83591 14 21538460 22005864 Gain Oral cancer
22 85535 14 48265939 80627188 Gain Oral cancer
23 88199 14 87604117 106349785 Gain Oral cancer
24 89600 15 18741744 19805989 Loss Oral cancer
25 89601 15 18741744 20060090 Gain Oral cancer
26 101423 16 36766 2592859 Gain Oral cancer
27 106087 16 85963377 88690615 Gain Oral cancer
28 118416 17 77385789 78462808 Gain Oral cancer
29 120365 18 24990733 76110993 Loss Oral cancer
30 124096 19 1 28500000 Gain Oral cancer
31 127007 19 232109 258746 Gain Oral cancer
32 133960 19 8275 236875 Loss Oral cancer
33 136827 2 133504494 133812256 Loss NCKAP5 Oral cancer
34 144179 2 242501268 242717042 Gain Oral cancer
35 150414 20 1 27100000 Gain Oral cancer
36 151218 20 18609 5869816 Gain Oral cancer
37 151741 20 24728423 25680524 Gain Oral cancer
38 152139 20 29436566 62363603 Gain Oral cancer
39 155361 20 55096989 59483462 Gain Oral cancer
40 155973 20 59483462 62194881 Gain Oral cancer
41 160312 22 134684 14797037 Loss Oral cancer
42 164561 22 37689087 37715408 Loss Oral cancer
43 166146 3 1 91700000 Deletion Oral cancer
44 166162 3 1 91700000 Loss Oral cancer
45 167591 3 121355348 144551988 Gain Oral cancer
46 169747 3 145187343 199379595 Gain Oral cancer
47 171086 3 163941201 164138371 Loss Oral cancer
48 172647 3 185019156 185896384 Gain Oral cancer
49 175342 3 39095 9150490 Loss CHL1 Oral cancer
50 175343 3 39095 9150490 Loss GRM7 Oral cancer
Sources

Expression for Oral Cancer

About this section
Search GEO for disease gene expression data for Oral Cancer.
Sources

Pathways for Oral Cancer

About this section

Pathways related to Oral Cancer according to GeneCards Suite gene sharing:

(show all 26)
# Super pathways Score Top Affiliating Genes
1
Endometrial cancer 36
Show member pathways
 12.79 TP53 MMP9 EGFR CDKN2A CDH1 CCND1
2
Drug metabolism - cytochrome P450 36
Show member pathways
 12.75 PTGS2 GSTT1 GSTM3 GSTM1 CYP1A1
3
Gastric cancer 36
Show member pathways
 12.58 TP53 RARB GSTT1 GSTM3 GSTM1 EGFR
4
Glioma 36
Show member pathways
 12.55 TP53 RARB MMP9 EGFR CDKN2A CDH1
5
Cell cycle 36 1
12.27 TP53 CDKN2A CDH1 CCND1
6
Proteoglycans in cancer 36
12.2 TP53 MMP9 MIR21 EGFR CCND1
7
MicroRNAs in cancer 36
12.1 TP53 PTGS2 MMP9 MIR345 MIR31 MIR21
8
Pathways in cancer 36
12.09 TP53 RARB PTGS2 MMP9 GSTT1 GSTM3
9
Integrated Breast Cancer Pathway 1
12.06 TP53 EGFR CDH1 CCND1
10
Colorectal Cancer Metastasis 63
12.02 TP53 PTGS2 MMP9 EGFR CDH1 CCND1
11
Fluid shear stress and atherosclerosis 36
12 TP53 MMP9 GSTT1 GSTM3 GSTM1
12
Interleukin-4 and 13 signaling 65
11.91 TP53 PTGS2 MMP9 CCND1
13
Spinal Cord Injury 1
11.91 TP53 PTGS2 MMP9 EGFR CCND1
14
Glioblastoma Multiforme 63
11.88 TP53 EGFR CDKN2A CCND1
15
Small cell lung cancer 36
11.78 TP53 RARB PTGS2 CCND1
16
Regulation of Wnt-mediated beta catenin signaling and target gene transcription 1
11.7 MMP9 CDH1 CCND1
17
Acetaminophen Pathway (therapeutic doses), Pharmacokinetics 60
Show member pathways
 11.69 GSTT1 GSTM1 CYP1A1
18
C-MYB transcription factor network 1
11.68 PTGS2 GSTM1 CCND1
19
Platinum drug resistance 36
11.63 TP53 GSTT1 GSTM3 GSTM1 CDKN2A
20
Photodynamic therapy-induced NF-kB survival signaling 1
Show member pathways
 11.57 PTGS2 MMP9 CCND1
21
Bladder cancer 36 1
11.5 TP53 MMP9 EGFR CDKN2A CDH1 CCND1
22
Photodynamic therapy-induced AP-1 survival signaling. 1
11.49 TP53 EGFR CDKN2A CCND1
23
Hepatitis C and Hepatocellular Carcinoma 1
11.48 TP53 PTGS2 CCND1
24
Aryl Hydrocarbon Receptor 1
11.44 PTGS2 EGFR CYP1A1
25
Signaling mediated by p38-alpha and p38-beta 1
11.28 TP53 PTGS2 KRT19
26
Naphthalene metabolism 23
11.08 GSTT1 GSTM1 CYP1A1
Sources

GO Terms for Oral Cancer

About this section

Biological processes related to Oral Cancer according to GeneCards Suite gene sharing:

(show all 21)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of cell proliferation GO:0008285 9.96 TP53 RARB PTGS2 MIR21 CDKN2A
2 response to drug GO:0042493 9.8 TP53 PTGS2 CYP1A1 CDH1 CCND1
3 negative regulation of apoptotic process GO:0043066 9.8 TP53 RARB PTGS2 MMP9 MIR21 EGFR
4 liver development GO:0001889 9.77 EGFR CYP1A1 CCND1
5 response to organic cyclic compound GO:0014070 9.73 PTGS2 EGFR CYP1A1 CCND1
6 response to estrogen GO:0043627 9.71 KRT19 GSTM3 CCND1
7 glutathione metabolic process GO:0006749 9.7 GSTT1 GSTM3 GSTM1
8 positive regulation of G1/S transition of mitotic cell cycle GO:1900087 9.67 EGFR CYP1A1 CCND1
9 embryo implantation GO:0007566 9.63 PTGS2 MMP9 MIR21
10 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.59 TP53 EGFR
11 regulation of neuroinflammatory response GO:0150077 9.58 PTGS2 MMP9
12 negative regulation of cartilage development GO:0061037 9.58 RARB MIR21
13 mitotic G1 DNA damage checkpoint GO:0031571 9.57 TP53 CCND1
14 xenobiotic catabolic process GO:0042178 9.55 GSTM3 GSTM1
15 cellular detoxification of nitrogen compound GO:0070458 9.51 GSTM3 GSTM1
16 nitrobenzene metabolic process GO:0018916 9.48 GSTM3 GSTM1
17 response to organic substance GO:0010033 9.46 PTGS2 CYP1A1 CDH1 CCND1
18 glutathione derivative biosynthetic process GO:1901687 9.43 GSTT1 GSTM3 GSTM1
19 response to UV-A GO:0070141 9.37 EGFR CCND1
20 positive regulation of protein phosphorylation GO:0001934 9.35 MMP9 MIR21 EGFR CDK2AP1 CCND1
21 positive regulation of apoptotic process GO:0043065 9.1 TP53 RARB PTGS2 MMP9 MIR21 CDKN2A

Molecular functions related to Oral Cancer according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 glutathione binding GO:0043295 9.26 GSTM3 GSTM1
2 enzyme binding GO:0019899 9.17 TP53 PTGS2 GSTM3 GSTM1 EGFR CYP1A1
3 MDM2/MDM4 family protein binding GO:0097371 9.16 TP53 CDKN2A
4 glutathione transferase activity GO:0004364 9.13 GSTT1 GSTM3 GSTM1
Sources

Sources for Oral Cancer

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....